What is valenTx?
valenTx Inc. is a medical device innovator based in Maple Grove, Minnesota, dedicated to developing non-surgical, implantable treatments for morbid obesity and type-II diabetes. The company's technology aims to provide a less invasive and more effective alternative to traditional bariatric surgeries and diabetes management strategies. By focusing on implantable devices, valenTx is positioning itself at the forefront of a growing market for advanced medical interventions in metabolic health.
How much funding has valenTx raised?
valenTx has raised a total of $25.2M across 3 funding rounds:
Series A
$772K
Series B
$20.3M
Debt
$4.1M
Series A (2004): $772K, investors not publicly disclosed
Series B (2009): $20.3M led by SV Health Investors, Sapient Capital Management, Covidien Ventures, Kaiser Permanente Ventures, EDF Ventures, and Affinity Capital Management
Debt (2014): $4.1M supported by SV Life Sciences and EDF Ventures
Key Investors in valenTx
SV Health Investors
SV Health Investors is a specialist investment firm backing innovative health care and life science companies, partnering with founders and management to provide capital, sector expertise and active support from early growth through scale and value creation.
Covidien Ventures
Covidien Ventures is a company that operates in the Consumer Services industry. It employs 10to19 people and has 1Mto5M of revenue. The company is headquartered in Mansfield, Massachusetts.
Kaiser Permanente Ventures
Kaiser Permanente Ventures is a national leader in strategic venture investing in healthcare, focusing on advancing healthcare innovation. The company partners with entrepreneurs to build promising healthcare solutions that provide clear value for patients, providers, and healthcare delivery systems.
What's next for valenTx?
With substantial enterprise-level backing, valenTx is poised for significant growth and product commercialization. The company's strategic focus will likely involve scaling its manufacturing capabilities, expanding its clinical trial programs, and navigating the regulatory landscape to bring its novel treatments to patients. Continued investment in research and development will be crucial to maintaining its competitive edge in the rapidly evolving medical device sector, particularly in the areas of obesity and diabetes management.
See full valenTx company page
